Pomalidomide | B1811

Pomalidomide is a derivative of Thalidomide (Cat. No. 2020) and a second-generation immunomodulatory drug. Pomalidomide targets the E3 ligase protein cereblon, preventing cereblon autoubiquitination activity. It has been shown to exert antiproliferative, antiangiogenic, and immunomodulatory effects against myeloma cells, modulating cell adhesion, decreasing production of key pro-survival cytokines, including TNF-α.

Pomalidomide is a derivative of Thalidomide (Cat. No. 2020) and a second-generation immunomodulatory drug. Pomalidomide targets the E3 ligase protein cereblon, preventing cereblon autoubiquitination activity. It has been shown to exert antiproliferative, antiangiogenic, and immunomodulatory effects against myeloma cells, modulating cell adhesion, decreasing production of key pro-survival cytokines, including TNF-α.

B1811 | Pomalidomide DataSheet

Alternate Name/Synonyms: 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione; CC4047

Appearance: Yellow solid

Formulation: N/A

CAS Number: 19171-19-8

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: N/A

Molecular Formula: C₁₃H₁₁N₃O₄

Molecular Weight: 273.24

Cell-Permeable?: Yes

Purity: ≥98%

Solubilities: DMSO (>8 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A second-generation immunomodulatory drug

MDL Number: MFCD12756407

PubChem CID: 134780

SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N

InChi: InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)

InChi Key: UVSMNLNDYGZFPF-UHFFFAOYSA-N